Medical Cannabis Studies


• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)


• batten-disease (6)

• benefits (9)

• breast-cancer (7)


• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)


• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)


• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)


• fibromyalgia (2)

• fibrosis (1)


• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)


• health-care (1)

• hiv (7)

• huntingtons-disease (1)


• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)


• krabbe-disease (4)


• liver (2)

• lung-cancer (2)

• lupus (1)


• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)


• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)


• pain (29)

• pancreatitis (1)

• prostate-cancer (2)


• schizophrenia (2)

• skin (1)

• sports (3)


• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid (2004)

    El sistema de receptores cannabinoides tiene el potencial de reducir tanto el da�o celular excitot�xico como oxidativo. Estos mecanismos celulares pueden ser la base del presunto efecto neuroprotector en modelos animales. El THC y otros cannabinoides pueden ser nuevos objetivos terap�uticos para el tratamiento de la esclerosis lateral amiotr�fica (ELA). View study

  • An endogenous cannabinoid (2-AG) is neuroprotective after brain injury (2001)

    Here we show that, after an injury to the brain of a mouse, Arachidonoyl glycerol (2-AG) may have a neuroprotective role in which the cannabinoid system is involved. We found a significant reduction of cerebral edema, better clinical recovery, reduced infarct volume and reduced hippocampal cell death compared to controls. View study

  • An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse (Documento PDF da�ado)

    View study

  • An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors (2017)

    View study

  • An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies (2017)

    This survey seeks to expand the survey previously done by Bergamaschi et al. in 2011 on the safety and side effects of cannabidiol (CBD), as well as updating literature. This paper focuses on clinical studies and the possible interactions of the CBD with other medications. View study

  • Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome (2016)

    This study demonstrates that CBD or cannabidiol helps reduce seizures of childhood epilepsy, and dravets syndrome. View study

  • Anandamide and 2-arachidonoylglycerol- pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids (2012)

    There is evidence suggesting that AEA and 2-AG possess specific pharmacological properties and that they also participate in different forms of synaptic plasticity and in different behavioral functions, such as learning and memory, reward and addiction, antinociception and anxiety. View study

  • Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors (2000)

    The results of this study indicate that cannabinoid receptors have a protective role against apoptosis induced by endocannabinoid anandamide (AEA) through vanilloid receptors. View study

  • Anti-inflammatory Potential of CB1-mediated CAMP Elevation in Mast Cells (2005)

    This research was based on defining the role of paper for CB1 in mast cells and identifying the signaling pathways that can mediate the suppressive effects of CB1 ligation in mast cell activation. The results show the complexity of the signaling of the co-expressed native cannabinoid receptors and suggest that some anti-inflammatory effects of the CB1 ligands can be attributed to a sustained increase in the anti-inflammatory potential of the elevation mediated by CB1 (cAMP). View study

  • Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-Induced Acute Pancreatitis in Mice (2012)

    The treatment with cannabidiol or O-1602 significantly improved the pathological changes of mice with experimental acute pancreatitis, showing anti-inflammatory effects. View study

  • Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells (2012)

    A study demonstrating that endogenous cannabinoid anandamide AEA inhibits the proliferation of cancer cells and induces cellular apoptosis, suggesting its therapeutic potential in the treatment of patients with human hepatocellular carcinoma. View study

  • Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy (2011)

    Findings that reveal the therapeutic potential of cannabinoids for the treatment of hepatocellular carcinoma, especially in advanced stages. View study

  • Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation (2000)

    THC (the main component of cannabis) induces apoptosis (cell death) of cancer cells in culture. Its intratumoral administration induced a considerable regression of malignant gliomas. View study

  • Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy (2007)

    Anandamide is potentially involved in the control of cancer growth directed both to the proliferation of tumor cells and to the angiogenic stimulation of the vasculature. View study

  • Antibacterial Cannabinoids from Cannabis sativa: A Structure-Activity Study (06/01/05)

    Marijuana contains antibacterial cannabinoids whose potential to address antibiotic resistance. The five major cannabinoids: cannabidiol CBD, cannabicyromen, cannabigerol, THC, and cannabinol showed potent activity against a variety of methicillin-resistant strains of Staphylococcus aureus. View study

  • Anticancer mechanisms of cannabinoids (2016)

    There is a lot of evidence that shows how cannabinoids can reduce cancer tumors in animals. These findings already serve as the basis for the development of studies that analyze the therapeutic potential of cannabinoids to fight cancer. View study

  • Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa (2014)

    Cannabidiol (CBD) is a non-psychotomimetic component of Cannabis sativa with great psychiatric potential, which includes its use as an antidepressant and anxiolytic compound. Studies with animal models, which perform a myriad of experiments, suggest that CBD exhibited anxiety and antidepressant effects. View study

  • Antimicrobial Activity of Cannabis sativa L. (2011)

    In the present study, the oil of the seeds, the petroleum ether and the methanol extracts of the whole plant of Cannabis sativa were tested against various organisms and fungi, demonstrating important microbial properties. View study

  • Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma (2006)

    A comparison of antitumor properties of different cannabinoids. The results obtained show that cannabidiol is the most potent inhibitor of the growth of cancer cells. View study

  • Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines (2004)

    In this study, the in vitro antiproliferative capacity of cannabidiol (CBD), a non-psychoactive cannabinoid compound, in U87 and U373 human glioma cell lines is evaluated. According to the results obtained, it could be concluded that non-psychoactive CBD was able to produce significant antitumor activity both in vitro and in vivo, suggesting a possible application of CBD as an antineoplastic agent View study

  • Antitumorigenic Effects of Cannabinoids beyond Apoptosis (2009)

    Cannabinoids may likewise affect cancer cell angiogenesis, migration, invasion, adhesion, and metastasization. View study

  • Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments (2014)

    Effectiveness of the instruments for the detection and evaluation of cannabis use disorders. View study

  • Assessment of the role of CB receptors in cannabinoid 1 anticonvulsant effects (2001)

    It has been shown that cannabinoids are anticonvulsants in the maximum electroshock. This study establishes a role for the CB1 receptor in modulating convulsive activity in an animal model. View study

  • Association of Herbal Cannabis Use With Negative Psychosocial Parameters in Patients With Fibromyalgia (2009)

    This research is based on the association of the use of herbal cannabis with negative psychosocial parameters in patients with fibromyalgia. It was concluded in this investigation that cannabinoids were used by 13% of patients referred with a diagnosis of fibromyalgia (FM). The association of the use of herbal cannabis with negative psychosocial parameters raises questions about the reason for this practice of self-medication. Although cannabinoids may offer some therapeutic effect, caution should be exercised with regard to any recommendation pending clarification of general health and psychosocial problems, especially for those who self-medicate. View study